ITM Isotope Technologies Munich
ITM is the largest non-carrier-added lutetium-177 supplier and the developer of ITM-11 (177Lu-edotreotide).
ITM supplies non-carrier-added 177Lu (EndolucinBeta), developed ITM-11 (COMPETE phase 3 positive in GEP-NETs, 2025), and is investing in 225Ac supply.
Pages like this
not linked directly; found by shared links- CompanyOrano Med
Shares Therapeutic isotope supply chain (Mo-99, Lu-177, Ac-225), Peptide receptor radionuclide therapy (PRRT), Radiopharmaceutical roadmap: iodine → lutetium → actinium, Somatostatin receptor 2.
- TrialCOMPETE
Shares 177Lu-edotreotide, Peptide receptor radionuclide therapy (PRRT), Somatostatin receptor 2, Neuroendocrine tumours.
- CompanyRayzeBio (BMS)
Shares Peptide receptor radionuclide therapy (PRRT), Radiopharmaceutical roadmap: iodine → lutetium → actinium, Targeted alpha therapy, Neuroendocrine tumours.
- PairingSSTR PET → PRRT
Shares 177Lu-edotreotide, Peptide receptor radionuclide therapy (PRRT), Somatostatin receptor 2, Neuroendocrine tumours.
- CompanyTerraPower Isotopes
Shares Therapeutic isotope supply chain (Mo-99, Lu-177, Ac-225), Radiopharmaceutical roadmap: iodine → lutetium → actinium, Targeted alpha therapy, Manufacturing cost and time for living and radioactive medicines.
- IdeaSSTR antagonist radioligands to increase tumour dose
Shares Peptide receptor radionuclide therapy (PRRT), Somatostatin receptor 2, Neuroendocrine tumours.
- CompanyRadioMedix
Shares Peptide receptor radionuclide therapy (PRRT), Somatostatin receptor 2, Targeted alpha therapy, Neuroendocrine tumours.
- ProductActinium-225 DOTATATE
Shares Peptide receptor radionuclide therapy (PRRT), Radiopharmaceutical roadmap: iodine → lutetium → actinium, Somatostatin receptor 2, Targeted alpha therapy.